RAPT Therapeutics Faces Delisting Concerns

Rapt Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRapt Therapeutics, Inc.
Form Type8-K
Filed DateMay 28, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

RAPT Therapeutics is on the chopping block for delisting.

AI Summary

RAPT Therapeutics, Inc. filed an 8-K on May 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective May 21, 2025. The company, formerly known as FLX Bio, Inc., is incorporated in Delaware and headquartered in South San Francisco, California.

Why It Matters

This filing indicates potential issues with RAPT Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.

Key Numbers

  • 001-38997 — Commission File Number (Identifies the company's filing with the SEC)
  • 47-3313701 — IRS Employer Identification No. (Tax identification number for the company)

Key Players & Entities

  • RAPT Therapeutics, Inc. (company) — Registrant
  • May 21, 2025 (date) — Earliest event reported
  • May 28, 2025 (date) — Date of report
  • FLX Bio, Inc. (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • South San Francisco, California (location) — Principal Executive Offices

FAQ

What specific listing rule or standard did RAPT Therapeutics fail to satisfy?

The filing does not specify the exact rule or standard that RAPT Therapeutics failed to satisfy, only that it is a notice of delisting or failure to satisfy a continued listing rule or standard.

What is the effective date of the delisting notice?

The earliest event reported, which is the notice of delisting or failure to satisfy a continued listing rule or standard, is dated May 21, 2025.

When was this 8-K form filed with the SEC?

This 8-K form was filed with the SEC on May 28, 2025.

What was RAPT Therapeutics' former company name?

RAPT Therapeutics, Inc. was formerly known as FLX Bio, Inc.

Where are RAPT Therapeutics' principal executive offices located?

RAPT Therapeutics' principal executive offices are located at 561 Eccles Avenue, South San Francisco, California, 94080.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding RAPT Therapeutics, Inc..

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.